Skip to main content
Fagron N.V. logo

Fagron N.V. — Investor Relations & Filings

Ticker · FAGR ISIN · BE0003874915 LEI · 549300TRKRUFK2RRG779 BR Manufacturing
Open in API
Filings indexed 1,987 across all filing types
Latest filing 2025-09-29 Share Issue/Capital Cha…
Country BE Belgium
Listing BR FAGR

About Fagron N.V.

https://fagron.com/

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Recent filings

Filing Released Lang Actions
Press release increase share capital 29 September 2025.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the issuance of 355,000 new shares following the exercise of subscription rights. It details the change in total share capital and the updated number of voting rights (denominator). This falls directly under the category of share capital changes and new share issues.
2025-09-29 English
Persbericht verhoging kapitaal 29 september 2025.pdf
Share Issue/Capital Change Classification · 100% confidence The document announces the issuance of 355,000 new shares resulting from the exercise of subscription rights (warrants). It provides updated figures for the company's share capital and total voting rights (the 'denominator'). This is a direct announcement of a change in share capital and issuance of new shares, which falls under the 'Share Issue/Capital Change' category.
2025-09-29 Dutch
Fagron announces the acquisition of UCP in North America and FDA inspection update
M&A Activity Classification · 95% confidence The document is a press release from Fagron announcing a strategic acquisition (UCP) and providing a regulatory update regarding FDA inspections. Because the primary purpose of the document is to announce a merger/acquisition (M&A) activity, it falls under the 'TAR' category. While it also contains regulatory information, the acquisition of a company is the headline event.
2025-09-25 Dutch
Fagron announces the acquisition of UCP in North America and FDA inspection update
M&A Activity Classification · 95% confidence The document is a press release announcing a strategic acquisition (UCP) and providing a regulatory update regarding FDA inspections. While it mentions an acquisition, it is a general corporate announcement rather than a formal M&A filing or a specific report. Since it does not fit into the specific categories of M&A (TAR) or Legal Proceedings (LTR) exclusively, and acts as a general regulatory announcement of material information, it is best classified as a Regulatory Filing (RNS).
2025-09-25 English
Fagron announces the acquisition of UCP in North America and FDA inspection update.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing a strategic acquisition (UCP) and providing a regulatory update regarding FDA inspections. Since it details a merger/acquisition activity and provides specific financial details about the transaction (enterprise value, revenue, EBITDA impact), it falls under M&A Activity. While it mentions regulatory matters, the primary driver of the announcement is the acquisition.
2025-09-25 English
Fagron kondigt de overname van UCP in Noord-Amerika aan en een update over de FDA-inspectie.pdf
M&A Activity Classification · 100% confidence The document is a press release from Fagron announcing a strategic acquisition (UCP in North America) and providing a regulatory update regarding FDA inspections. Since the primary purpose of the document is to announce a merger/acquisition activity, it falls under the M&A Activity category. While it also contains regulatory information, the acquisition of a company for $41.5 million is the headline event, making 'TAR' the most accurate classification.
2025-09-25 Dutch

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.